

## Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins - notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's *in situ* hybridization detection products - which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota.

The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

With thousands of products in its portfolio, Bio-Techne generated approximately \$643 million in net sales in fiscal 2018 and has over 2,100 employees worldwide.

## Bio-Techne Introduces GMP Small Molecules for Stem Cell Therapy Development

Aug 8 2018, 9:00 AM EDT

## Bio-Techne Declares Dividend

Aug 7 2018, 7:00 AM EDT

## Bio-Techne Releases Fourth Quarter Fiscal 2018 Results

Aug 7 2018, 7:00 AM EDT

## Stock Overview

Symbol	TECH
Exchange	Nasdaq
Market Cap	6.78b
Last Price	\$180.50
52-Week	\$117.419998 - \$183.899993

08/17/2018 04:00 PM EDT

## Investor Relations

David Clair  
T: 646-277-1266  
[ir@bio-techne.com](mailto:ir@bio-techne.com)

## Management Team

### Charles (Chuck) Kummeth

President and Chief Executive Officer

### Jim Hippel

Chief Financial Officer

### David Eansor

President, Protein Sciences Segment

### Kim Kelderman

President, Diagnostics and Genomics

### Brenda Furlow

General Counsel, Secretary and Chief Compliance Officer

## Bio-Techne Corporation

614 McKinley Place NE  
Minneapolis, MN 55413

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.